An observational study in Pulmonary Embolism, sponsored by Hospital St. Joseph, Marseille, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Hospital St. Joseph, Marseille, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Pulmonary Embolism with a site in France — 24 open to participants now, 27 under way, 4 of them phase 3. Pulmonary Embolism · France.
Among the 138 studies in Pulmonary Embolism with a site in France, this one is the 54th largest by enrollment of the 63 observational ones that give a count, is one of 14 that started in 2020, is one of 63 observational ones, and was the 93rd registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →24 of the 138 studies in Pulmonary Embolism with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18+
University of Calgary · Sites in France, Belgium, Canada and 4 more countries
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 23 · Phase 4 10
First in 1992; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Median enrollment 556 across the 74 interventional studies, 302 across the 63 observational. Of the 99 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 138 have an industry lead sponsor. The 10 most frequent:
Hospital St. Joseph, Marseille, France is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Hospital St. Joseph, Marseille, France has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
7 of the studies in Pulmonary Embolism with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103670University Hospital, BrestVentilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism | 2026-12-22 |
| NCT06166329University Hospital, RouenInterest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study | 2027-02 |
| NCT05015153University Hospital, BrestImpact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study | 2027-02-25 |
| NCT07850453Ribocure Pharmaceuticals ABVortosiran for VTE Prevention | 2027-07 |
| NCT06386107Centre Hospitalier Universitaire de Saint EtienneThrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 138 studies in Pulmonary Embolism with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study COVID-EP is to classify all the complications occurring after the diagnosis of pulmonary embolism in patients tested initially COVID-19 positive and negative by RT-PCR (on nasopharyngeal sample) during the peak of the pandemic in France (April 2020). The patients will be followed for 1 year in order to provide clinical and paraclinical data not yet published in the literature. In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed. The collected complications will then be compared between each of the 3 following groups: [PCR-COVID 19-Neg \& Sero-COVID 19-Neg] versus [PCR-COVID 19-Neg \& Sero-COVID 19-Pos] versus [PCR-COVID 19-Pos].
Patient diagnosed and / or hospitalized for PE in April 2020 (the COVID-19 pandemic peak)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Having a microbiological diagnosis confirming COVID-19 infection (ie positive RT-PCR on nasopharyngeal swab) and/or clinical/CT signs
Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
Diagnostic Test: Serology test for COVID-19
* Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs * Having been tested positive in a serological test for COVID-19 at M3
* Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs * Having been tested negative in a serological test for COVID-19 at M3
In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts: 1. ELISA test 2. Rapid Diagnostic tests (only if ELISA test is positive)
% of patients for each group presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 6 months after PE diagnosis.
PE complications : * Chronic interstitial pathology, or * Recurrence of PE, or * Pulmonary hypertension, or * Death.
Time frame: 6 months after PE diagnosis
% of patients for each group and subgroup presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 12 months after PE diagnosis.
PE complications : * Chronic interstitial pathology, or * Recurrence of PE, or * Pulmonary hypertension, or * Death.
Time frame: 12 months after PE diagnosis
% of patients in each group presenting the occurrence of each of the following events at each follow-up (3 months, 6 months and 12 months after PE diagnosis).
PE complications : * Chronic interstitial pathology, or * Recurrence of PE, or * Pulmonary hypertension, or * Death.
Time frame: 3, 6 and 12 months after PE diagnosis
% of patients diagnosed COVID - at M0 by RT-PCR on nasopharyngeal swab and diagnosed COVID + by serology 3 months after PE diagnosis
Time frame: 3 months after PE diagnosis
Effectiveness of the different category of treatments used in all patients and in the groups: % of occurrence of PE complications for each categories of treatments
Category of treatments: * Heparin + AVK * Heparin + DOAC PE complication : * Chronic interstitial pathology, or * Recurrence of PE, or * Pulmonary hypertension, or * Death.
Time frame: 12 months after PE diagnosis
Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with occurrence of bleeding complications for each categories of treatments
Category of treatments: * Heparin + AVK * Heparin + DOAC Bleeding complications: classification 1-2-3-5 according to BARC
Time frame: 12 months after PE diagnosis
Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with no occurrence of complications for each categories of treatments
Category of treatments: * Heparin + AVK * Heparin + DOAC
Time frame: 12 months after PE diagnosis
Effectiveness of the different category of treatments used in all patients and in the groups: duration of Heparin treatment (number of day)
Category of treatments: * Heparin + AVK * Heparin + DOAC
Time frame: 12 months after PE diagnosis
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2020 to primary completion in Sep 2021, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital St. Joseph, Marseille, France